Cost-effectiveness Analysis of Levofloxacin and Gatifoxacin in the Treatment of Lower Respiratory Tract Infections / 药物流行病学杂志
Chinese Journal of Pharmacoepidemiology
; (4)2005.
Article
Dans Zh
| WPRIM
| ID: wpr-578973
Responsable en Bibliothèque :
WPRO
ABSTRACT
Objective:
To evaluate the cost-effectiveness of levofloxacin and gatifoxacin in the treatment of lower respiratory tract infections.Method:
The clinical data of levofloxacin and gatifoxacin in the treatment of lower respiratory tract infections were collected with the evidence-based medicine method and were evaluated with pharmacoeconomic cost-effectiveness analysis.Result:
The cure rates of two drugs were 64.29%(57.70%,70.88%),and 81.43%(70.05%, 92.81%)and the cost-effectiveness ratios were 1.90 and 5.79 respectively.The?C/?E was 20.37.Conclusion:
The cost-effectiveness analysis indicated that the cost-effectivenss ratio of levofloxacin is superior to that of gatifoxacin though the cure efficacy of gatifoxacin for lower respiratory tract infections is better.
Texte intégral:
1
Indice:
WPRIM
Type d'étude:
Health_economic_evaluation
langue:
Zh
Texte intégral:
Chinese Journal of Pharmacoepidemiology
Année:
2005
Type:
Article